POMALYST® (pomalidomide) Treatment Option
Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial - The
OPTIMISMM Trial - Slideset Download - Clin Onc June 2018 | CCO
Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse | Leukemia
IMiDs, especially pomalidomide and dexamethasone, strongly synergized... | Download Scientific Diagram
APOLLO trial results: Addition of daratumumab to pomalidomide + dexamethasone in relapsed/refractory multiple myeloma
Isatuximab-Pomalidomide-Dexamethasone Versus Pomalidomide-Dexamethasone in East Asian Patients With Relapsed/Refractory Multiple Myeloma: ICARIA-MM Subgroup Analysis - Clinical Lymphoma, Myeloma and Leukemia
FDA approves Sarclisa regimen for adults with advanced multiple myeloma
Phase II Trials of Pomalidomide and Dexamethasone in Combination with Either Cyclophosphamide or Bortezomib in Relapsed or Refractory MM | Research To Practice
Elotuzumab (Empliciti) Drug Info
Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma | NEJM
Pomalidomide/Dexamethasone Combination in Relapsed/Refractory Multiple Myeloma | Research To Practice
Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma - ScienceDirect
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study - The Lancet
Results of IFM 2014-01 Study (IxPd) From EHA 2022 | Int Myeloma Fn
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study - The Lancet Oncology
Best response to pomalidomide plus dexamethasone treatment. | Download Scientific Diagram
![PDF] Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/c2d9ab11b5739b401b8d3d2d135f5d895e4a8519/14-Figure3-1.png "PDF] Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. | Semantic Scholar")
PDF] Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. | Semantic Scholar
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial - The Lancet Oncology
ASCO 2019 Dr. Richardson on Isatuximab | Int Myeloma Fn
